Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Technical Analysis
Nasdaq Composite: Pivot points » 08:24
11/29/22
11/29
08:24
11/29/22
08:24
$COMP

Nasdaq Composite

/

+

The following are the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$COMP Nasdaq Composite
/

+

$COMP Nasdaq Composite
/

+

$COMP Nasdaq Composite
/

+

$COMP Nasdaq Composite
/

+

$COMP Nasdaq Composite
/

+

$COMP Nasdaq Composite
/

+

Hot Stocks
Mainz Biomed appoints Amy Levin as VP, regulatory affairs » 08:14
11/29/22
11/29
08:14
11/29/22
08:14
MYNZ

Mainz Biomed

$9.00 /

+ (+0.00%)

, RHHBY

Roche

$41.09 /

+0.03 (+0.07%)

Mainz Biomed (MYNZ)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MYNZ Mainz Biomed
$9.00 /

+ (+0.00%)

RHHBY Roche
$41.09 /

+0.03 (+0.07%)

MYNZ Mainz Biomed
$9.00 /

+ (+0.00%)

10/25/22 Cantor Fitzgerald
Mainz Biomed initiated with an Overweight at Cantor Fitzgerald
06/21/22 H.C. Wainwright
Mainz Biomed initiated with a Buy at H.C. Wainwright
RHHBY Roche
$41.09 /

+0.03 (+0.07%)

11/15/22 Truist
Biogen price target raised to $350 from $265 at Truist
11/15/22 Truist
Eli Lilly price target raised to $421 from $400 at Truist
11/15/22 Stifel
Roche downgraded to Hold from Buy at Stifel
11/15/22 Cowen
Roche downgraded to Market Perform on 'bare' pipeline at Cowen
RHHBY Roche
$41.09 /

+0.03 (+0.07%)

  • 26
    Jan
RHHBY Roche
$41.09 /

+0.03 (+0.07%)

RHHBY Roche
$41.09 /

+0.03 (+0.07%)

Yesterday
Recommendations
Genmab risk/reward favorable into arbitration ruling, says Morgan Stanley » 16:42
11/28/22
11/28
16:42
11/28/22
16:42
GMAB

Genmab

$44.81 /

+0.51 (+1.15%)

, JNJ

Johnson & Johnson

$177.31 /

+0.11 (+0.06%)

Morgan Stanley analyst…

Morgan Stanley analyst Matthew Harrison names Genmab (GMAB) a "Catalyst Driving Idea" while keeping an Underweight rating on the shares with a $34 price target. Genmab and Johnson & Johnson (JNJ) are in a second arbitration over Darzalex Faspro and a ruling is expected in 2023. The analyst reviewed the redacted copy of the license agreement and believes Genmab "may have a valid claim." The license agreement states that the milestone payments and royalties are paid on a licensed product-by-licensed product basis, and for each licensed product, royalty payments shall commence on the date of the first commercial sale of such licensed product and expiring on the later of 13 years thereafter or the expiration of relevant patents, Harrison tells investors in a research note. He says the key issue is whether Genmab is entitled to additional milestone payments and a new 13-year royalty term from Darzalex Faspro's first commercial sale date. Harrison views Genmab's risk/reward as favorable into the 2023 ruling.

ShowHide Related Items >><<
JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

GMAB Genmab
$44.81 /

+0.51 (+1.15%)

GMAB Genmab
$44.81 /

+0.51 (+1.15%)

11/17/22 Societe Generale
Genmab price target raised to DKK 2,160 from DKK 1,950 at Societe Generale
11/17/22 AlphaValue/Baader
Genmab upgraded to Add from Reduce at AlphaValue/Baader
11/14/22 JPMorgan
Genmab price target raised to DKK 3,450 from DKK 2,900 at JPMorgan
11/14/22 William Blair
Genmab initiated with a Market Perform at William Blair
JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

11/17/22 Credit Suisse
Johnson & Johnson initiated with a Neutral at Credit Suisse
11/02/22 Morgan Stanley
Abiomed upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/22 Deutsche Bank
Abiomed downgraded to Hold from Buy at Deutsche Bank
11/01/22 Piper Sandler
Abiomed downgraded to Neutral from Overweight at Piper Sandler
JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

GMAB Genmab
$44.81 /

+0.51 (+1.15%)

JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

GMAB Genmab
$44.81 /

+0.51 (+1.15%)

JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

Recommendations
Aveva price target raised to 3,225 GBp from 3,113 GBp at Berenberg » 13:12
11/28/22
11/28
13:12
11/28/22
13:12
AVEVF

Aveva

$36.91 /

+ (+0.00%)

Berenberg analyst Nay Soe…

Berenberg analyst Nay Soe Naing raised the firm's price target on Aveva to 3,225 GBp from 3,113 GBp and keeps a Hold rating on the shares.

ShowHide Related Items >><<
AVEVF Aveva
$36.91 /

+ (+0.00%)

AVEVF Aveva
$36.91 /

+ (+0.00%)

11/09/22 Deutsche Bank
Aveva price target raised to 3,100 GBp from 2,400 GBp at Deutsche Bank
11/09/22 Morgan Stanley
Aveva price target raised to 2,750 GBp from 2,675 GBp at Morgan Stanley
11/07/22 Exane BNP Paribas
Aveva downgraded to Neutral from Outperform at Exane BNP Paribas
09/28/22 UBS
Aveva downgraded to Neutral from Buy at UBS
AVEVF Aveva
$36.91 /

+ (+0.00%)

On The Fly
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 09:46
11/28/22
11/28
09:46
11/28/22
09:46
ATVI

Activision Blizzard

$74.73 /

+1.21 (+1.65%)

, MSFT

Microsoft

$245.77 /

-1.83 (-0.74%)

, BUD

AB InBev

$59.05 /

+2.55 (+4.51%)

, WYNN

Wynn Resorts

$78.31 /

+3.43 (+4.58%)

, MLCO

Melco Resorts & Entertainment

$7.14 /

+0.545 (+8.27%)

, BWA

BorgWarner

$41.95 /

-0.26 (-0.62%)

, FSLR

First Solar

$169.00 /

-2.5 (-1.46%)

, XPEV

XPeng

$6.98 /

-0.09 (-1.27%)

, WSM

Williams-Sonoma

$117.50 /

-4.71 (-3.85%)

, BYND

Beyond Meat

$12.40 /

-0.34 (-2.67%)

, TSN

Tyson Foods

$65.88 /

-1.86 (-2.75%)

, LI

Li Auto

$16.41 /

-0.4 (-2.38%)

, NIO

Nio

$10.08 /

-0.09 (-0.88%)

, HEAR

Turtle Beach

$9.62 /

+0.32 (+3.44%)

, U

Unity

$34.84 /

-0.8 (-2.24%)

, HSON

Hudson Global

$22.50 /

+0.45 (+2.04%)

, LYV

Live Nation

$68.31 /

+0.05 (+0.07%)

, DKNG

DraftKings

$14.55 /

-0.58 (-3.83%)

Institutional investors…

ShowHide Related Items >><<
XPEV XPeng
$6.98 /

-0.09 (-1.27%)

WYNN Wynn Resorts
$78.31 /

+3.43 (+4.58%)

WSM Williams-Sonoma
$117.50 /

-4.71 (-3.85%)

U Unity
$34.84 /

-0.8 (-2.24%)

TSN Tyson Foods
$65.88 /

-1.86 (-2.75%)

NIO Nio
$10.08 /

-0.09 (-0.88%)

MSFT Microsoft
$245.77 /

-1.83 (-0.74%)

MLCO Melco Resorts & Entertainment
$7.14 /

+0.545 (+8.27%)

LYV Live Nation
$68.31 /

+0.05 (+0.07%)

LI Li Auto
$16.41 /

-0.4 (-2.38%)

HSON Hudson Global
$22.50 /

+0.45 (+2.04%)

HEAR Turtle Beach
$9.62 /

+0.32 (+3.44%)

FSLR First Solar
$169.00 /

-2.5 (-1.46%)

DKNG DraftKings
$14.55 /

-0.58 (-3.83%)

BYND Beyond Meat
$12.40 /

-0.34 (-2.67%)

BWA BorgWarner
$41.95 /

-0.26 (-0.62%)

BUD AB InBev
$59.05 /

+2.55 (+4.51%)

ATVI Activision Blizzard
$74.73 /

+1.21 (+1.65%)

ATVI Activision Blizzard
$74.73 /

+1.21 (+1.65%)

11/28/22 JPMorgan
Activision Blizzard price target lowered to $86 from $95 at JPMorgan
11/28/22 Wells Fargo
Wells Fargo upgrades Activision Blizzard to Overweight with $95 price target
11/28/22 Morgan Stanley
Activision Blizzard upgraded to Overweight from Equal Weight at Morgan Stanley
11/28/22 Truist
Activision Blizzard upgraded to Buy from Hold at Truist
MSFT Microsoft
$245.77 /

-1.83 (-0.74%)

BUD AB InBev
$59.05 /

+2.55 (+4.51%)

11/28/22 JPMorgan
JPMorgan double upgrades AB InBev with transition 'well underway'
11/28/22 JPMorgan
AB InBev upgraded to Overweight from Underweight at JPMorgan
10/28/22 Credit Suisse
AB InBev price target lowered to EUR 56 from EUR 58 at Credit Suisse
10/11/22 Morgan Stanley
AB InBev price target lowered to EUR 52 from EUR 54 at Morgan Stanley
WYNN Wynn Resorts
$78.31 /

+3.43 (+4.58%)

11/28/22 Jefferies
Macau concession renewals removes overhang for incumbents, says Jefferies
11/28/22 JPMorgan
Wynn Resorts upgraded to Overweight from Neutral at JPMorgan
11/21/22 Morgan Stanley
Wynn Resorts initiated with an Equal Weight at Morgan Stanley
10/31/22 Gordon Haskett
Gordon Haskett wonders if 'more going on' as Fertitta takes stake in Wynn
MLCO Melco Resorts & Entertainment
$7.14 /

+0.545 (+8.27%)

11/28/22 JPMorgan
Melco Resorts & Entertainment upgraded to Overweight from Neutral at JPMorgan
10/17/22 Credit Suisse
Melco downgraded to Neutral at Credit Suisse ahead of Q3 reports
10/17/22 Credit Suisse
Melco Resorts & Entertainment downgraded to Neutral at Credit Suisse
BWA BorgWarner
$41.95 /

-0.26 (-0.62%)

11/28/22 Morgan Stanley
BorgWarner upgraded to Equal Weight from Underweight at Morgan Stanley
11/23/22 Citi
BorgWarner price target raised to $44 from $37 at Citi
09/28/22 Citi
BorgWarner price target lowered to $37 from $45 at Citi
09/09/22 BofA
BorgWarner price target lowered to $75 from $78 at BofA
FSLR First Solar
$169.00 /

-2.5 (-1.46%)

11/28/22 JPMorgan
First Solar downgraded to Neutral from Overweight at JPMorgan
11/14/22 Deutsche Bank
First Solar initiated with a Buy at Deutsche Bank
11/10/22 Morgan Stanley
New California 'NEM 3.0' proposal 'screens positive,' says Morgan Stanley
11/10/22 Argus
First Solar price target raised to $176 from $123 at Argus
XPEV XPeng
$6.98 /

-0.09 (-1.27%)

11/28/22 Jefferies
XPeng downgraded to Underperform at Jefferies ahead of 'challenging year'
11/28/22 Jefferies
XPeng downgraded to Underperform from Hold at Jefferies
11/22/22 DBS Bank
XPeng initiated with a Buy at DBS Bank (earlier)
11/17/22 UBS
XPeng upgraded to Buy from Neutral at UBS
WSM Williams-Sonoma
$117.50 /

-4.71 (-3.85%)

11/28/22 Morgan Stanley
Williams-Sonoma downgraded to Underweight from Equal Weight at Morgan Stanley
11/21/22 Barclays
Williams-Sonoma downgraded to Equal Weight from Overweight at Barclays
11/21/22 Barclays
RH downgraded to Equal Weight from Overweight at Barclays
11/18/22 Wells Fargo
Williams-Sonoma price target lowered to $120 from $170 at Wells Fargo
BYND Beyond Meat
$12.40 /

-0.34 (-2.67%)

11/28/22 Barclays
Beyond Meat downgraded to Underweight from Equal Weight at Barclays
11/23/22 Goldman Sachs
Beyond Meat price target lowered to $5 from $14 at Goldman Sachs
11/10/22 Bernstein
Beyond Meat price target lowered to $10 from $22 at Bernstein
11/10/22 Mizuho
Beyond Meat price target lowered to $11 from $27 at Mizuho
TSN Tyson Foods
$65.88 /

-1.86 (-2.75%)

11/28/22 Barclays
Tyson Foods downgraded to Underweight from Equal Weight at Barclays
11/15/22 BMO Capital
Tyson Foods price target lowered to $75 from $90 at BMO Capital
11/09/22 BofA
Tyson Foods downgraded to Underperform from Neutral at BofA
10/27/22 Piper Sandler
Tyson Foods price target lowered to $68 from $79 at Piper Sandler
LI Li Auto
$16.41 /

-0.4 (-2.38%)

11/28/22 Jefferies
Li Auto initiated with a Buy at Jefferies
11/25/22 DBS Bank
Li Auto initiated with a Buy at DBS Bank
10/28/22 Barclays
Li Auto price target lowered to $25 from $40 at Barclays
09/06/22 Morgan Stanley
September 'crunch time' for China EV makers, says Morgan Stanley
NIO Nio
$10.08 /

-0.09 (-0.88%)

11/28/22 Jefferies
Nio assumed with a Hold at Jefferies
11/21/22 Deutsche Bank
'Worse may finally be over' for Nio, says Deutsche Bank
11/17/22 UBS
Nio downgraded to Neutral at UBS on expectations for ET5 execution challenges
11/17/22 UBS
Nio downgraded to Neutral from Buy at UBS
HEAR Turtle Beach
$9.62 /

+0.32 (+3.44%)

11/28/22 Roth Capital
Turtle Beach initiated with a Buy at Roth Capital
11/04/22 DA Davidson
Turtle Beach price target lowered to $7.50 from $14 at DA Davidson
11/04/22 Maxim
Turtle Beach price target lowered to $10 from $17 at Maxim
08/09/22 Lake Street
Turtle Beach price target lowered to $18 from $32 at Lake Street
U Unity
$34.84 /

-0.8 (-2.24%)

11/28/22 Morgan Stanley
Unity resumed with an Equal Weight at Morgan Stanley
11/21/22 Citi
Unity price target lowered to $54 from $61 at Citi
11/17/22 Stifel
Unity price target raised to $40 from $30 at Stifel
11/15/22 Goldman Sachs
Unity reinstated with a Neutral at Goldman Sachs
HSON Hudson Global
$22.50 /

+0.45 (+2.04%)

11/28/22 EF Hutton
Hudson Global initiated with a Buy at EF Hutton
LYV Live Nation
$68.31 /

+0.05 (+0.07%)

11/28/22 Citi
Live Nation upgraded to Buy from Neutral at Citi
11/22/22 Redburn
Redburn starts Live Nation with a Neutral
11/22/22 Redburn
Live Nation initiated with a Neutral at Redburn
11/01/22 Morgan Stanley
Live Nation price target lowered to $95 from $110 at Morgan Stanley
DKNG DraftKings
$14.55 /

-0.58 (-3.83%)

11/28/22 JPMorgan
DraftKings downgraded to Underweight from Neutral at JPMorgan
11/22/22 Susquehanna
DraftKings hack likely to affect user confidence, says Susquehanna
11/21/22 Piper Sandler
Scale of reported DraftKings hack not known, says Piper Sandler
11/21/22 Morgan Stanley
DraftKings assumed with an Overweight at Morgan Stanley
XPEV XPeng
$6.98 /

-0.09 (-1.27%)

WYNN Wynn Resorts
$78.31 /

+3.43 (+4.58%)

WSM Williams-Sonoma
$117.50 /

-4.71 (-3.85%)

U Unity
$34.84 /

-0.8 (-2.24%)

TSN Tyson Foods
$65.88 /

-1.86 (-2.75%)

NIO Nio
$10.08 /

-0.09 (-0.88%)

MSFT Microsoft
$245.77 /

-1.83 (-0.74%)

MLCO Melco Resorts & Entertainment
$7.14 /

+0.545 (+8.27%)

LYV Live Nation
$68.31 /

+0.05 (+0.07%)

LI Li Auto
$16.41 /

-0.4 (-2.38%)

HSON Hudson Global
$22.50 /

+0.45 (+2.04%)

HEAR Turtle Beach
$9.62 /

+0.32 (+3.44%)

FSLR First Solar
$169.00 /

-2.5 (-1.46%)

DKNG DraftKings
$14.55 /

-0.58 (-3.83%)

BYND Beyond Meat
$12.40 /

-0.34 (-2.67%)

BWA BorgWarner
$41.95 /

-0.26 (-0.62%)

BUD AB InBev
$59.05 /

+2.55 (+4.51%)

ATVI Activision Blizzard
$74.73 /

+1.21 (+1.65%)

XPEV XPeng
$6.98 /

-0.09 (-1.27%)

WYNN Wynn Resorts
$78.31 /

+3.43 (+4.58%)

U Unity
$34.84 /

-0.8 (-2.24%)

TSN Tyson Foods
$65.88 /

-1.86 (-2.75%)

NIO Nio
$10.08 /

-0.09 (-0.88%)

MSFT Microsoft
$245.77 /

-1.83 (-0.74%)

LYV Live Nation
$68.31 /

+0.05 (+0.07%)

LI Li Auto
$16.41 /

-0.4 (-2.38%)

FSLR First Solar
$169.00 /

-2.5 (-1.46%)

DKNG DraftKings
$14.55 /

-0.58 (-3.83%)

BYND Beyond Meat
$12.40 /

-0.34 (-2.67%)

BWA BorgWarner
$41.95 /

-0.26 (-0.62%)

BUD AB InBev
$59.05 /

+2.55 (+4.51%)

ATVI Activision Blizzard
$74.73 /

+1.21 (+1.65%)

XPEV XPeng
$6.98 /

-0.09 (-1.27%)

WYNN Wynn Resorts
$78.31 /

+3.43 (+4.58%)

WSM Williams-Sonoma
$117.50 /

-4.71 (-3.85%)

U Unity
$34.84 /

-0.8 (-2.24%)

TSN Tyson Foods
$65.88 /

-1.86 (-2.75%)

NIO Nio
$10.08 /

-0.09 (-0.88%)

MLCO Melco Resorts & Entertainment
$7.14 /

+0.545 (+8.27%)

LYV Live Nation
$68.31 /

+0.05 (+0.07%)

LI Li Auto
$16.41 /

-0.4 (-2.38%)

HEAR Turtle Beach
$9.62 /

+0.32 (+3.44%)

FSLR First Solar
$169.00 /

-2.5 (-1.46%)

DKNG DraftKings
$14.55 /

-0.58 (-3.83%)

BYND Beyond Meat
$12.40 /

-0.34 (-2.67%)

BWA BorgWarner
$41.95 /

-0.26 (-0.62%)

BUD AB InBev
$59.05 /

+2.55 (+4.51%)

ATVI Activision Blizzard
$74.73 /

+1.21 (+1.65%)

XPEV XPeng
$6.98 /

-0.09 (-1.27%)

WYNN Wynn Resorts
$78.31 /

+3.43 (+4.58%)

WSM Williams-Sonoma
$117.50 /

-4.71 (-3.85%)

U Unity
$34.84 /

-0.8 (-2.24%)

TSN Tyson Foods
$65.88 /

-1.86 (-2.75%)

NIO Nio
$10.08 /

-0.09 (-0.88%)

MSFT Microsoft
$245.77 /

-1.83 (-0.74%)

MLCO Melco Resorts & Entertainment
$7.14 /

+0.545 (+8.27%)

LYV Live Nation
$68.31 /

+0.05 (+0.07%)

LI Li Auto
$16.41 /

-0.4 (-2.38%)

HEAR Turtle Beach
$9.62 /

+0.32 (+3.44%)

FSLR First Solar
$169.00 /

-2.5 (-1.46%)

DKNG DraftKings
$14.55 /

-0.58 (-3.83%)

BYND Beyond Meat
$12.40 /

-0.34 (-2.67%)

BUD AB InBev
$59.05 /

+2.55 (+4.51%)

ATVI Activision Blizzard
$74.73 /

+1.21 (+1.65%)

Conference/Events
JPMorgan Euro utility/clean energy analyst has analyst/industry conference call » 09:43
11/28/22
11/28
09:43
11/28/22
09:43
NGG

National Grid

$61.89 /

+ (+0.00%)

European Utilities &…

European Utilities & Clean Energy Analyst Mahbubani takes an in-depth look at the European energy industry on an Analyst/Industry conference call to be held on November 28 at 10 am. Webcast Link

ShowHide Related Items >><<
NGG National Grid
$61.89 /

+ (+0.00%)

NGG National Grid
$61.89 /

+ (+0.00%)

11/15/22 Societe Generale
National Grid upgraded to Buy from Hold at Societe Generale
11/15/22 Societe Generale
National Grid upgraded to Buy from Hold at Societe Generale
11/08/22 JPMorgan
National Grid resumed with an Overweight at JPMorgan
10/28/22 Credit Suisse
National Grid price target lowered to 1,150 GBp from 1,225 GBp at Credit Suisse
Hot Stocks
Philips launches compact ultrasound system at RSNA 2022 » 09:06
11/28/22
11/28
09:06
11/28/22
09:06
PHG

Philips

$14.83 /

+0.545 (+3.82%)

Royal Philips announced…

Royal Philips announced the global launch of a next-generation compact portable ultrasound solution at the Radiological Society of North America annual meeting. Philips' new Compact 5000 Series aims to bring the diagnostic quality associated with premium cart-based ultrasound systems to more patients. Designed for portability and versatility without compromising image quality or performance, the Compact 5000 series facilitates first-time-right ultrasound exams for more patients.

ShowHide Related Items >><<
PHG Philips
$14.83 /

+0.545 (+3.82%)

PHG Philips
$14.83 /

+0.545 (+3.82%)

10/31/22 JPMorgan
Philips price target lowered to EUR 10.90 from EUR 18.80 at JPMorgan
10/26/22 Barclays
Philips price target lowered to EUR 19 from EUR 38 at Barclays
10/25/22 HSBC
Philips downgraded to Reduce from Hold at HSBC
10/18/22 Morgan Stanley
Philips initiated with an Equal Weight at Morgan Stanley
PHG Philips
$14.83 /

+0.545 (+3.82%)

PHG Philips
$14.83 /

+0.545 (+3.82%)

Technical Analysis
Nasdaq Composite: Pivot points » 08:24
11/28/22
11/28
08:24
11/28/22
08:24
$COMP

Nasdaq Composite

/

+

The following are the…

The following are the pivot points for the . Pivot High: 11243.965, Pivot Low: 11188.775. These were calculated using the DeMark method. It is generally believed to be bullish when price breaks out above the pivot high or bearish when price breaks down below the pivot low.

ShowHide Related Items >><<
$COMP Nasdaq Composite
/

+

$COMP Nasdaq Composite
/

+

$COMP Nasdaq Composite
/

+

$COMP Nasdaq Composite
/

+

$COMP Nasdaq Composite
/

+

$COMP Nasdaq Composite
/

+

Hot Stocks
Lineage Cell announces Genentech launch of OpRegen study for GA » 08:10
11/28/22
11/28
08:10
11/28/22
08:10
LCTX

Lineage Cell Therapeutics

$1.43 /

-0.035 (-2.39%)

, RHHBY

Roche

$41.06 /

+0.44 (+1.08%)

Lineage Cell Therapeutics…

Lineage Cell Therapeutics (LCTX) announced that its partner Genentech, a member of the Roche Group (RHHBY), has launched a Phase 2a, multicenter, open-label, single arm clinical study of RG6501 a retinal pigment epithelial cell therapy. The study is intended to optimize subretinal surgical delivery and evaluate the safety and activity of OpRegen in approximately 30, and up to 60 patients with geographic atrophy GA secondary to age-related macular degeneration. The primary objectives of the study are to evaluate (i) the proportion of patients with subretinal surgical delivery of OpRegen to target regions under the retina, and (ii) to evaluate the safety of subretinal surgical delivery of OpRegen as measured by the incidence and severity of procedure-related adverse events at 3 months following surgery. A key secondary objective is to evaluate the proportion of patients with qualitative improvement in retinal structure, as determined by Optical Coherence Tomography imaging, within 3 months following surgery. RG6501, OpRegen, is currently being developed under an exclusive worldwide collaboration between Lineage, Roche and Genentech. "We are excited for the launch of this Phase 2a study, where one of the key objectives is to optimize the delivery of OpRegen to achieve the best outcomes," stated Seppi Lin, Vice President of OMNI Early Clinical Development at Genentech. "This study will provide key insights for the future development of the OpRegen program. Geographic Atrophy, GA , secondary to AMD is a disease area of high unmet need with no approved therapies, and we are committed to developing effective and innovative medicines for patients with serious eye diseases."

ShowHide Related Items >><<
RHHBY Roche
$41.06 /

+0.44 (+1.08%)

LCTX Lineage Cell Therapeutics
$1.43 /

-0.035 (-2.39%)

LCTX Lineage Cell Therapeutics
$1.43 /

-0.035 (-2.39%)

11/01/22 Baird
Baird starts Lineage Cell Therapeutics with an Outperform, $5 price target
11/01/22 Baird
Lineage Cell Therapeutics initiated with an Outperform at Baird
06/14/22 B. Riley
B. Riley starts 'deep value play' Lineage Cell with Buy, $4 target
06/14/22 B. Riley
Lineage Cell Therapeutics initiated with a Buy at B. Riley
RHHBY Roche
$41.06 /

+0.44 (+1.08%)

11/15/22 Truist
Biogen price target raised to $350 from $265 at Truist
11/15/22 Truist
Eli Lilly price target raised to $421 from $400 at Truist
11/15/22 Stifel
Roche downgraded to Hold from Buy at Stifel
11/15/22 Cowen
Roche downgraded to Market Perform on 'bare' pipeline at Cowen
RHHBY Roche
$41.06 /

+0.44 (+1.08%)

LCTX Lineage Cell Therapeutics
$1.43 /

-0.035 (-2.39%)

RHHBY Roche
$41.06 /

+0.44 (+1.08%)

RHHBY Roche
$41.06 /

+0.44 (+1.08%)

LCTX Lineage Cell Therapeutics
$1.43 /

-0.035 (-2.39%)

Upgrade
JPMorgan double upgrades AB InBev with transition 'well underway' » 06:42
11/28/22
11/28
06:42
11/28/22
06:42
BUD

AB InBev

$56.50 /

+0.13 (+0.23%)

JPMorgan analyst Jared…

JPMorgan analyst Jared Dinges upgraded AB InBev to Overweight from Underweight with a price target of $70, up from $45. The analyst sees "scope for earnings outperformance" and says the company's "rapidly deleveraging balance sheet provides optionality." AB InBev's transition to a "higher-quality top-line growth story is well underway," Dinges tells investors in a research note. The analyst models 8.8% organic sales growth in fiscal 2023, supported by sustainable Latin America momentum, and "contrary to investor concerns" he sees upside in the U.S. and China. The company can deliver EBITDA growth above its medium term guide in 2023 "with best-in-class" teens earnings growth from 2023 onwards, Dinges contends. He views AB InBev's valuation as attractive at current levels.

ShowHide Related Items >><<
BUD AB InBev
$56.50 /

+0.13 (+0.23%)

BUD AB InBev
$56.50 /

+0.13 (+0.23%)

11/28/22 JPMorgan
AB InBev upgraded to Overweight from Underweight at JPMorgan
10/28/22 Credit Suisse
AB InBev price target lowered to EUR 56 from EUR 58 at Credit Suisse
10/11/22 Morgan Stanley
AB InBev price target lowered to EUR 52 from EUR 54 at Morgan Stanley
10/10/22 Barclays
AB InBev price target lowered to EUR 74 from EUR 78 at Barclays
BUD AB InBev
$56.50 /

+0.13 (+0.23%)

BUD AB InBev
$56.50 /

+0.13 (+0.23%)

BUD AB InBev
$56.50 /

+0.13 (+0.23%)

BUD AB InBev
$56.50 /

+0.13 (+0.23%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.